Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Update

Posted by Anthony Miller on Feb 12th, 2026

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Get Free Report) saw a significant growth in short interest in January. As of January 30th, there was short interest totaling 24,900 shares, a growth of 1,055.5% from the January 15th total of 2,155 shares. Currently, 16.6% of the company’s stock are sold short. Based on an average trading volume of 3,724 shares, the short-interest ratio is presently 6.7 days. Based on an average trading volume of 3,724 shares, the short-interest ratio is presently 6.7 days. Currently, 16.6% of the company’s stock are sold short.

Amplify Weight Loss Drug & Treatment ETF Stock Up 0.6%

THNR traded up $0.15 during midday trading on Thursday, hitting $26.31. 690 shares of the company traded hands, compared to its average volume of 4,144. The company’s 50-day moving average is $25.79 and its 200 day moving average is $24.38. The firm has a market capitalization of $3.95 million, a PE ratio of 24.31 and a beta of 0.61. Amplify Weight Loss Drug & Treatment ETF has a 52 week low of $18.56 and a 52 week high of $27.28.

Amplify Weight Loss Drug & Treatment ETF Dividend Announcement

The firm also recently announced an annual dividend, which was paid on Wednesday, December 31st. Shareholders of record on Tuesday, December 30th were issued a dividend of $0.4132 per share. This represents a yield of 162.0%. The ex-dividend date of this dividend was Tuesday, December 30th.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC lifted its holdings in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Free Report) by 5.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,891 shares of the company’s stock after buying an additional 1,215 shares during the period. Jane Street Group LLC owned about 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent reporting period.

Amplify Weight Loss Drug & Treatment ETF Company Profile

(Get Free Report)

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.